Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: GlobeNewswire
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved therapies for the overall treatment of SSc Norwood, MA, May 27, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed their final visit in the Company’s RESOLVE-1 Phase 3 trial of lenabasum for the treatment of systemic sclerosis. Topline results from the study are on track for summer 2020. “We would like to express our sincere gratitude to our staff, our clinical collaborators and the study participants for their commitment and dedication leading to the study completing on time even in the midst of a global pandemic,” said Yuval Cohen, Ph.D, Chief Executive Of
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual MeetingGlobeNewswire
- Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology [Seeking Alpha]Seeking Alpha
- Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength [Yahoo! Finance]Yahoo! Finance
- Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer [Yahoo! Finance]Yahoo! Finance
CRBP
Sec Filings
- 4/11/24 - Form 4
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form 8-K
- CRBP's page on the SEC website